News Releases

This information is part of the archives and is no longer current and may no longer be accurate.

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009
DateTitle 
Dec 13, 2017DURECT Announces NDA Acceptance of Indivior's RBP-7000 Risperidone Monthly DepotPrinter Friendly Version
Nov 01, 2017DURECT Corporation Announces Third Quarter 2017 Financial Results and Provides Corporate UpdatePrinter Friendly Version
Oct 26, 2017DURECT Corporation Invites You to Join its Third Quarter 2017 Earnings Conference CallPrinter Friendly Version
Oct 19, 2017DURECT Announces Top-line Results from the PERSIST Phase 3 Trial of POSIMIR® (SABER®-Bupivacaine) Did Not Meet Primary Efficacy EndpointPrinter Friendly Version
Oct 02, 2017DURECT and Indivior PLC Sign a $17.5 Million Patent Purchase AgreementPrinter Friendly Version
Sep 20, 2017DURECT Appoints Dr. Myriam Theeuwes as Senior Vice President, Clinical DevelopmentPrinter Friendly Version
Sep 05, 2017DURECT to Participate in Upcoming Healthcare ConferencesPrinter Friendly Version
Aug 08, 2017DURECT Corporation Announces Second Quarter 2017 Financial Results and Provides Corporate UpdatePrinter Friendly Version
Aug 08, 2017ORADUR®-Methylphenidate ER Capsule Achieves Primary Endpoint in Phase 3 Study in ADHD in TaiwanPrinter Friendly Version
Aug 01, 2017DURECT Corporation Invites You to Join its Second Quarter 2017 Earnings Conference CallPrinter Friendly Version
Jun 22, 2017DURECT Completes Enrollment in PERSIST, Phase 3 trial for POSIMIR®Printer Friendly Version
Jun 19, 2017DURECT's Collaboration with Sandoz Clears HSR Review and is EffectivePrinter Friendly Version
May 10, 2017DURECT Corporation Announces First Quarter 2017 Financial Results and Provides Corporate UpdatePrinter Friendly Version
May 08, 2017DURECT and Sandoz have Signed a $293 Million Development and Commercialization Agreement for POSIMIR® (SABER®-Bupivacaine) Covering the United StatesPrinter Friendly Version
May 04, 2017DURECT Corporation Invites You to Join its First Quarter 2017 Earnings Conference CallPrinter Friendly Version
Apr 24, 2017DURECT Announces Presentation of Data from a Phase 1b Study of DUR-928 in Nonalcoholic Steatohepatitis (NASH) at The International Liver Congress™ 2017Printer Friendly Version
Apr 17, 2017DURECT to Present Clinical Data at the International Liver Congress™ 2017Printer Friendly Version
Apr 03, 2017DURECT to Present at the H.C. Wainwright NASH Investor ConferencePrinter Friendly Version
Mar 14, 2017DURECT Corporation Announces Fourth Quarter and Full Year 2016 Financial Results and Update of ProgramsPrinter Friendly Version
Feb 24, 2017DURECT Corporation Invites You to Join its Fourth Quarter 2016 Earnings Conference CallPrinter Friendly Version
Jan 30, 2017DURECT Corporation Announces Update on DUR-928 Development ProgramPrinter Friendly Version